<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nuechterlein N</submitter><funding>National Institute of Neurological Disorders and Stroke</funding><funding>National Science Foundation Graduate Research Fellowship Program</funding><funding>NINDS NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>41</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11390787</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>148(1)</volume><pubmed_abstract>Oligodendroglioma, IDH-mutant and 1p/19q-codeleted has highly variable outcomes that are strongly influenced by patient age. The distribution of oligodendroglioma age is non-Gaussian and reportedly bimodal, which motivated our investigation of age-associated molecular alterations that may drive poorer outcomes. We found that elevated HOXD12 expression was associated with both older patient age and shorter survival in the TCGA (FDR &lt; 0.01, FDR = 1e-5) and the CGGA (p = 0.03, p &lt; 1e-3). HOXD12 gene body hypermethylation was associated with older age, higher WHO grade, and shorter survival in the TCGA (p &lt; 1e-6, p &lt; 0.001, p &lt; 1e-3) and with older age and higher WHO grade in Capper et al. (p &lt; 0.002, p = 0.014). In the TCGA, HOXD12 gene body hypermethylation and elevated expression were indep</pubmed_abstract><journal>Acta neuropathologica</journal><pubmed_title>HOXD12 defines an age-related aggressive subtype of oligodendroglioma.</pubmed_title><pmcid>PMC11390787</pmcid><funding_grant_id>R35 CA253119</funding_grant_id><funding_grant_id>DGE-1762114</funding_grant_id><funding_grant_id>Intramural Research Program</funding_grant_id><pubmed_authors>Gilbert MR</pubmed_authors><pubmed_authors>McGranahan T</pubmed_authors><pubmed_authors>Rajan S</pubmed_authors><pubmed_authors>Nuechterlein N</pubmed_authors><pubmed_authors>Shelbourn A</pubmed_authors><pubmed_authors>Aldape K</pubmed_authors><pubmed_authors>Shapiro LG</pubmed_authors><pubmed_authors>Holland EC</pubmed_authors><pubmed_authors>Ha V</pubmed_authors><pubmed_authors>Cimino S</pubmed_authors><pubmed_authors>Arora S</pubmed_authors><pubmed_authors>Cimino PJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>HOXD12 defines an age-related aggressive subtype of oligodendroglioma.</name><description>Oligodendroglioma, IDH-mutant and 1p/19q-codeleted has highly variable outcomes that are strongly influenced by patient age. The distribution of oligodendroglioma age is non-Gaussian and reportedly bimodal, which motivated our investigation of age-associated molecular alterations that may drive poorer outcomes. We found that elevated HOXD12 expression was associated with both older patient age and shorter survival in the TCGA (FDR &lt; 0.01, FDR = 1e-5) and the CGGA (p = 0.03, p &lt; 1e-3). HOXD12 gene body hypermethylation was associated with older age, higher WHO grade, and shorter survival in the TCGA (p &lt; 1e-6, p &lt; 0.001, p &lt; 1e-3) and with older age and higher WHO grade in Capper et al. (p &lt; 0.002, p = 0.014). In the TCGA, HOXD12 gene body hypermethylation and elevated expression were indep</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-06-02T23:22:34.551Z</modification><creation>2025-04-04T07:41:06.93Z</creation></dates><accession>S-EPMC11390787</accession><cross_references><pubmed>39259414</pubmed><doi>10.1007/s00401-024-02802-1</doi></cross_references></HashMap>